Proteros and Priaxon Announce Lead Discovery Collaboration on Protein-Protein Interaction Targets
News Apr 09, 2013
The combination of Proteros’ structure guided discovery with Priaxon’s PPI-directed drug discovery platforms will be focused on the identification of novel small molecule modulators for PPI targets. As part of this collaboration, Proteros will apply its integrated Lead Discovery expertise and technologies in the field of structural biology, biophysics and screening. Priaxon will apply its proprietary drug discovery platform Priaxplore®, which combines a proprietary PPI focused chemical space with special tailor made chemoinformatic methods for the identification of potential PPI modulators.
“The combination of Proteros’ strength in structural biology and biophysics with the Priaxon’s PPI focused drug discovery platform Priaxplore® forms an excellent basis to make PPI targets of high interest addressable by small molecule modulators" said Dr. Juergen Kolb, CEO of Priaxon.
Dr. Torsten Neuefeind, CEO of Proteros, stated: "We are very pleased to have formed this relationship with Priaxon. Both companies have complementary platforms as well as an established track-record. PPIs are a big challenge in drug discovery and the use of structural information, computational chemistry and Priaxons’ validated chemistry approach allows us to respond to the industry demand for such targets in a unique manner”.
Multifunctional Protein Contributes to Blood Cell DevelopmentNews
In a new finding, investigators have uncovered in mouse cells a previously unknown job for a protein called nup98. In addition to helping control the movement of molecules in and out of the nucleus of the cell, they found that it also helps direct the development of blood cells, enabling immature blood stem cells to differentiate into many specialized mature cell types.READ MORE
New Opportunities for Type 2 Diabetes Drug Discovery: Researchers Determine Glucagon Receptor StructureNews
Complex structure of a class B GPCR bound to an analogue of its endogenous ligand ignites new excitement in GPCR research.READ MORE